Livagen

Livagen
Identifiers
  • (4S)-5-[[(2S)-3-carboxy-1-[[(1S)-1-carboxyethyl]amino]-1-oxopropan-2-yl]amino]-4-[[(2S)-2,6-diaminohexanoyl]amino]-5-oxopentanoic acid
PubChem CID
ChemSpider
Chemical and physical data
FormulaC18H31N5O9
Molar mass461.472 g·mol−1
3D model (JSmol)
  • C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)N
  • InChI=1S/C18H31N5O9/c1-9(18(31)32)21-17(30)12(8-14(26)27)23-16(29)11(5-6-13(24)25)22-15(28)10(20)4-2-3-7-19/h9-12H,2-8,19-20H2,1H3,(H,21,30)(H,22,28)(H,23,29)(H,24,25)(H,26,27)(H,31,32)/t9-,10-,11-,12-/m0/s1
  • Key:IKVDKWACACMDLR-BJDJZHNGSA-N

Livagen is a tetrapeptide with the sequence KEDA or Lys-Glu-Asp-Ala. It is one of a number of small peptides developed in Russia in the late 1990s and early 2000s which have antiinflammatory and purported anti-aging effects, and are now widely sold over the internet as anti-aging products though with relatively limited evidence to support these claims.[1][2][3][4][5][6][7][8]

See also

References

  1. ^ Khavinson VK, Malinin VV, Chalisova NI, Grigor'ev EI (2002). "[Tissue-specific action of peptides in tissue culture of rats of various ages]". Advances in Gerontology = Uspekhi Gerontologii. 9: 95–100. PMID 12096446.
  2. ^ Khavinson VK, Lezhava TA, Malinin VV (January 2004). "Effects of short peptides on lymphocyte chromatin in senile subjects". Bulletin of Experimental Biology and Medicine. 137 (1): 78–81. doi:10.1023/b:bebm.0000024393.40560.05. PMID 15085253.
  3. ^ Lezhava T, Monaselidze J, Kadotani T, Dvalishvili N, Buadze T (April 2006). "Anti-aging peptide bioregulators induce reactivation of chromatin". Georgian Medical News (133): 111–115. PMID 16705247.
  4. ^ Lezhava T, Jokhadze T (April 2007). "Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals". Annals of the New York Academy of Sciences. 1100 (1): 387–399. Bibcode:2007NYASA1100..387L. doi:10.1196/annals.1395.043. PMID 17460203.
  5. ^ Dzhokhadze TA, Ganozishvili MN, Lezhava TA (September 2008). "[The effect of heavy metal ions and peptide bioregulators on the expression of chromosome fragile sites in the individuals of different age groups and breast cancer patients]". Georgian Medical News (162): 11–14. PMID 18830022.
  6. ^ Dzhokhadze TA, Buadze TZ, Gaiozishvili MN, Kakauridze NG, Lezhava TA (November 2014). "[Genomic instability in atherosclerosis]". Georgian Medical News (236): 82–86. PMID 25541832.
  7. ^ Kuznik BI, Khasanova NB, Ryzhak GA, Mezsheriakova IE, Khavinson VK (2020). "[The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology.]". Advances in Gerontology = Uspekhi Gerontologii. 33 (1): 159–164. PMID 32362099.
  8. ^ Lezhava T, Jokhadze T, Monaselidze J, Buadze T, Gaiozishvili M, Sigua T, et al. (February 2023). "Epigenetic Modification Under the Influence of Peptide Bioregulators on the "Old" Chromatin". Georgian Medical News (335): 79–83. PMID 37042594.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.